This company develops a platform that integrates generative AI with real-world evidence to advance precision medicine. The technology links multi-omics biomarkers to drug response and adverse-event risk, providing pharmacogenomic recommendations. This capability accelerates drug development timelines and supports clinicians in delivering optimized treatment protocols.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for determining drug selection and dosage often overlook individual genetic variations, leading to potential adverse drug reactions, reduced treatment efficacy, and increased healthcare costs. Analyzing potential drug interactions and associated health risks can be time-consuming and costly.
Solution
PGxAI offers an AI-powered pharmacogenetics platform that analyzes individual genetic profiles to optimize drug selection and dosage. The platform uses proprietary AI algorithms and a comprehensive drug database of over 730 medications to provide rapid and accurate analysis of drug-gene interactions. PGxAI's technology assesses potential risks associated with combined medication intake and identifies potential health risks, such as thrombosis and atherosclerosis. The platform aims to deliver personalized medicine solutions that improve patient safety and treatment outcomes.
Target Audience
The primary target audience includes healthcare providers, medical professionals, and clinical researchers seeking to improve drug therapy outcomes through personalized medicine.
Features
- AI-powered analysis of pharmacogenetic data for personalized drug therapy
- Extensive drug database covering over 730 medications across clinical specialties
- Holistic drug interaction analysis to identify potential risks of combined medications
- Identification of potential health risks, such as thrombosis and atherosclerosis
- Cost-effective analysis at approximately $0.055 per drug analysis
- Advanced AI algorithms for pharmacogenetic data analysis